Innovative Access Agreements

Business man pointing at bar graph on paper

A potential payer solution for Cell & Gene Therapies

A US and European perspective

Payer concerns over increasing cost of therapies and uncertainty of clinical data have led to a growing interest in market access tools. These tools have many names and definitions, often referred to as innovative (IAA) or alternative access agreements (AAA). For the purpose of this review we will refer to them collectively as IAA. The agreements can be split into two key categories: finance-based, designed to reduce uncertainties over budget impact and cost; and outcome-based, designed to reduce clinician uncertainties over drug performance.

Download White Paper

We’re here to support your success from clinical to commercial – and beyond.

How can we help you today?